0IV3 logo

Geron CorporationLSE:0IV3 Stock Report

Market Cap US$808.3m
Share Price
US$1.27
US$3.44
63.2% undervalued intrinsic discount
1Y-14.0%
7D0.2%
1D
Portfolio Value
​
View

Geron Corporation

LSE:0IV3 Stock Report

Market Cap: US$808.3m

Geron (0IV3) Stock Overview

A commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. More details

0IV3 fundamental analysis
Snowflake Score
Valuation5/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 93.2% below our estimate of its fair value

Earnings are forecast to grow 62.54% per year

Trading at good value compared to peers and industry

Risk Analysis

Volatile share price over the past 3 months compared to the UK market


0IV3 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Geron Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Geron
Historical stock prices
Current Share PriceUS$1.27
52 Week HighUS$2.00
52 Week LowUS$1.04
Beta0.68
1 Month Change-16.78%
3 Month Change-22.80%
1 Year Change-13.95%
3 Year Change-62.68%
5 Year Change-11.41%
Change since IPO-37.38%

Recent News & Updates

Recent updates

Shareholder Returns

0IV3GB BiotechsGB Market
7D0.2%-1.1%0.08%
1Y-14.0%21.6%19.1%

Return vs Industry: 0IV3 underperformed the UK Biotechs industry which returned 23.8% over the past year.

Return vs Market: 0IV3 underperformed the UK Market which returned 19.8% over the past year.

Price Volatility

Is 0IV3's price volatile compared to industry and market?
0IV3 volatility
0IV3 Average Weekly Movement10.0%
Biotechs Industry Average Movement9.1%
Market Average Movement5.7%
10% most volatile stocks in GB Market11.9%
10% least volatile stocks in GB Market3.1%

Stable Share Price: 0IV3's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0IV3's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
1990258Harout Semerjianwww.geron.com

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.

Geron Corporation Fundamentals Summary

How do Geron's earnings and revenue compare to its market cap?
0IV3 fundamental statistics
Market capUS$808.32m
Earnings (TTM)-US$67.31m
Revenue (TTM)US$196.12m
4.1x
P/S Ratio
-11.9x
P/E Ratio

Is 0IV3 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0IV3 income statement (TTM)
RevenueUS$196.12m
Cost of RevenueUS$76.54m
Gross ProfitUS$119.57m
Other ExpensesUS$186.88m
Earnings-US$67.31m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.10
Gross Margin60.97%
Net Profit Margin-34.32%
Debt/Equity Ratio52.3%

How did 0IV3 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/05/28 15:53
End of Day Share Price 2026/05/28 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Geron Corporation is covered by 18 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas BuchananBrean Capital Historical (Janney Montgomery)
Thomas ShraderBTIG
Charles DuncanCitizens JMP Securities, LLC